1 month retatrutide Weight Loss Treatment Explained Retatrutide: The New Triple-Agonist Weight
Description
An additional recent study found that GLP-1 action on human pancreatic islet alpha-cells was mediated independently of any paracrine signalling, as preventing insulin and somatostatin signalling did not affect the inhibition of glucagon secretion
doi: 10.1507/endocrj.EJ24-0286
Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, et al
doi:10.1016/j.biocon.2003.07.002
According to NICE, Wegovy should only be used within specialist weight management services, generally for people with a BMI 35 kg/m (lower thresholds may apply for some minority ethnic groups) with at least one weight-related comorbidity, and for a maximum duration of 2 years
